Chromatin as an old and new anticancer target

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Chromatin modifiers are frequently mutated in various cancers.
• Current cancer treatments often target DNA damage, despite mutations in chromatin regulators.
• A gap exists in treating cancers with chromatin-related genetic alterations.

Purpose of the Study:

• To introduce the concept of 'chromatin damage' as a therapeutic target.
• To highlight overlooked chromatin-targeting chemotherapeutic agents.
• To explore novel chromatin-damaging agents for cancer treatment.

Main Methods:

• Review of existing literature on chromatin modifiers and cancer.
• Analysis of small molecules that induce non-genetic damage to protein-DNA interactions.
• Focus on anthracyclines as a case study for chromatin-targeting agents.

Main Results:

• Established the concept of 'chromatin damage' distinct from DNA damage.
• Identified anthracyclines as clinically relevant chromatin-damaging agents.
• Highlighted the potential of overlooked chromatin-targeting therapies.

Conclusions:

• 'Chromatin damage' represents a new paradigm for cancer therapy.
• Anthracyclines and similar agents offer therapeutic avenues for chromatin-deranged cancers.
• Further research into chromatin-damaging agents can improve cancer treatment outcomes.